| Literature DB >> 22189549 |
Ugo Boggi1, Fabio Vistoli, Gabriella Amorese, Rosa Giannarelli, Alberto Coppelli, Rita Mariotti, Lorenzo Rondinini, Massimiliamo Barsotti, Alberto Piaggesi, Anna Tedeschi, Stefano Signori, Nelide De Lio, Margherita Occhipinti, Emanuela Mangione, Diego Cantarovich, Stefano Del Prato, Franco Mosca, Piero Marchetti.
Abstract
We report on our single-center experience with pancreas transplantation alone (PTA) in 71 patients with type 1 diabetes, and a 4-year follow-up. Portal insulin delivery was used in 73.2% of cases and enteric drainage of exocrine secretion in 100%. Immunosuppression consisted of basiliximab (76%), or thymoglobulin (24%), followed by mycophenolate mofetil, tacrolimus, and low-dose steroids. Actuarial patient and pancreas survival at 4 years were 98.4% and 76.7%, respectively. Relaparatomy was needed in 18.3% of patients. Restored endogenous insulin secretion resulted in sustained normalization of fasting plasma glucose levels and HbA1c concentration in all technically successful transplantations. Protenuria (24-hour) improved significantly after PTA. Renal function declined only in recipients with pretransplant glomerular filtration rate (GFR) greater than 90 ml/min, possibly as a result of correction of hyperfiltration following normalization of glucose metabolism. Further improvements were recorded in several cardiovascular risk factors, retinopathy, and neuropathy. We conclude that PTA was an effective and reasonably safe procedure in this single-center experience.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22189549 PMCID: PMC3280011 DOI: 10.1900/RDS.2011.8.259
Source DB: PubMed Journal: Rev Diabet Stud ISSN: 1613-6071